Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,197
archived clinical trials in
Atrial Fibrillation

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated:  6/27/2016
Clinical Research Facility
475
mi
from 43215
Weston, WI
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated: 6/27/2016
Clinical Research Facility
475
mi
from 43215
Weston, WI
Click here to add this to my saved trials
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated:  6/27/2016
Research Site
mi
from 43215
Bahía Blanca,
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Status: Enrolling
Updated: 6/27/2016
Research Site
mi
from 43215
Bahía Blanca,
Click here to add this to my saved trials
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Status: Enrolling
Updated:  12/15/2016
Beaumont Health System
171
mi
from 43215
Royal Oak, MI
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation
Status: Enrolling
Updated: 12/15/2016
Beaumont Health System
171
mi
from 43215
Royal Oak, MI
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Cardiology Consultants Of Orange County Med. Group Inc
1962
mi
from 43215
Anaheim, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Cardiology Consultants Of Orange County Med. Group Inc
1962
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Oracle Clinical Research, Inc.
1960
mi
from 43215
Anaheim, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Oracle Clinical Research, Inc.
1960
mi
from 43215
Anaheim, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
WCCT Global, LLC
1964
mi
from 43215
Costa Mesa, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
WCCT Global, LLC
1964
mi
from 43215
Costa Mesa, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Long Beach VA Medical Center
1972
mi
from 43215
Long Beach, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Long Beach VA Medical Center
1972
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Spectrum Clinical Research
1923
mi
from 43215
Moreno Valley, CA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Spectrum Clinical Research
1923
mi
from 43215
Moreno Valley, CA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Chase Medical Research, LLC
532
mi
from 43215
Waterbury, CT
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Chase Medical Research, LLC
532
mi
from 43215
Waterbury, CT
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
ALL Medical Research, LLC
973
mi
from 43215
Cooper City, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
ALL Medical Research, LLC
973
mi
from 43215
Cooper City, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
The Cardiac And Vascular Institute Research Foundation, Llc
711
mi
from 43215
Gainesville, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
The Cardiac And Vascular Institute Research Foundation, Llc
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Acrc Cardiology
937
mi
from 43215
Lake Worth, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Acrc Cardiology
937
mi
from 43215
Lake Worth, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
The Heart Institute at Largo
832
mi
from 43215
Largo, FL
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
The Heart Institute at Largo
832
mi
from 43215
Largo, FL
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Columbus Regional Research Institute
523
mi
from 43215
Columbus, GA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Columbus Regional Research Institute
523
mi
from 43215
Columbus, GA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Community Clinical Research Center
140
mi
from 43215
Anderson, IN
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Community Clinical Research Center
140
mi
from 43215
Anderson, IN
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Midwest Heart & Vascular Specialists, LLC
623
mi
from 43215
Overland Park, KA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Midwest Heart & Vascular Specialists, LLC
623
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Cambridge Medical Trials
797
mi
from 43215
Alexandria, LA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Cambridge Medical Trials
797
mi
from 43215
Alexandria, LA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Castlerock Clinical Research Consultants, LLC
751
mi
from 43215
Tulsa, OK
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Castlerock Clinical Research Consultants, LLC
751
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Capital Area Research
323
mi
from 43215
Camp Hill, PA
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Capital Area Research
323
mi
from 43215
Camp Hill, PA
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Tennessee Center for Clinical Trials
362
mi
from 43215
Tullahoma, TN
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Tennessee Center for Clinical Trials
362
mi
from 43215
Tullahoma, TN
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Texas Cardiac Arrhythmia Research Foundation
1058
mi
from 43215
Austin, TX
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Texas Cardiac Arrhythmia Research Foundation
1058
mi
from 43215
Austin, TX
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Utah Cardiology PC
1515
mi
from 43215
Layton, UT
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Utah Cardiology PC
1515
mi
from 43215
Layton, UT
Click here to add this to my saved trials
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated:  1/5/2017
Local Institution
1700
mi
from 43215
Edmonton,
A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation
Status: Enrolling
Updated: 1/5/2017
Local Institution
1700
mi
from 43215
Edmonton,
Click here to add this to my saved trials
Use of Electronic Personal Health Records to Improve Medication Adherence
The Use of Electronic Personal Health Records to Improve Medication Adherence Among Non-Valvular Atrial Fibrillation Patients: A Pilot Study
Status: Enrolling
Updated:  1/10/2017
Parkview Research Center; Parkview Health
139
mi
from 43215
Fort Wayne, IN
Use of Electronic Personal Health Records to Improve Medication Adherence
The Use of Electronic Personal Health Records to Improve Medication Adherence Among Non-Valvular Atrial Fibrillation Patients: A Pilot Study
Status: Enrolling
Updated: 1/10/2017
Parkview Research Center; Parkview Health
139
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
699
mi
from 43215
Mobile, AL
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
699
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
182
mi
from 43215
Troy, MI
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
182
mi
from 43215
Troy, MI
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
111
mi
from 43215
Akron, OH
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
111
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
96
mi
from 43215
Cincinnati, OH
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
96
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
323
mi
from 43215
Camp Hill, PA
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
323
mi
from 43215
Camp Hill, PA
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
995
mi
from 43215
Houston, TX
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
1817
mi
from 43215
Walla Walla, WA
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
1817
mi
from 43215
Walla Walla, WA
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
329
mi
from 43215
Milwaukee, WI
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
329
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated:  1/13/2017
GSK Investigational Site
5386
mi
from 43215
Capital Federal,
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Status: Enrolling
Updated: 1/13/2017
GSK Investigational Site
5386
mi
from 43215
Capital Federal,
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
618
mi
from 43215
Dothan, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
618
mi
from 43215
Dothan, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
700
mi
from 43215
Mobile, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
700
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
556
mi
from 43215
Montgomery, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
556
mi
from 43215
Montgomery, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
476
mi
from 43215
Pell City, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
476
mi
from 43215
Pell City, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
524
mi
from 43215
Tuscaloosa, AL
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
524
mi
from 43215
Tuscaloosa, AL
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1481
mi
from 43215
Cottonwood, AZ
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1481
mi
from 43215
Cottonwood, AZ
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1639
mi
from 43215
Tucson, AZ
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
698
mi
from 43215
Fort Smith, AR
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
698
mi
from 43215
Fort Smith, AR
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1949
mi
from 43215
Carlsbad, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1949
mi
from 43215
Carlsbad, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
2034
mi
from 43215
Carmichael, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
2034
mi
from 43215
Carmichael, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1941
mi
from 43215
Corona, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1941
mi
from 43215
Corona, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1956
mi
from 43215
Laguna Hills, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1956
mi
from 43215
Laguna Hills, CA
Click here to add this to my saved trials
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
1975
mi
from 43215
Long Beach, CA
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
1975
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials